Bridging from Eliquis to Warfarin: No Enoxaparin Bridge Required
When switching from apixaban (Eliquis) to warfarin, you do NOT need enoxaparin bridging—start warfarin and a parenteral anticoagulant simultaneously at the time of the next scheduled Eliquis dose, then discontinue the parenteral anticoagulant when INR reaches therapeutic range (≥2.0 for 2 consecutive days). This typically takes 5-7 days of overlap.
The Switching Protocol
The FDA-approved Eliquis prescribing information provides clear guidance 1:
Step-by-step approach:
- Stop Eliquis at the time of the next scheduled dose
- Start warfarin AND enoxaparin together at that exact time point
- Continue enoxaparin at therapeutic doses (1 mg/kg subcutaneously every 12 hours OR 1.5 mg/kg once daily) 2
- Monitor INR starting on day 3-4 of warfarin therapy
- Discontinue enoxaparin once INR ≥2.0 on two consecutive measurements (typically 5-7 days) 2
Why This Differs from Traditional "Bridging"
This is NOT bridging in the traditional sense—it's overlap therapy. The distinction matters:
- Traditional bridging (stopping warfarin → using enoxaparin → restarting warfarin) is used when interrupting warfarin for procedures
- Overlap therapy (starting both simultaneously) is used when initiating warfarin from another anticoagulant
The 2022 ACCP guidelines 3 and 2014 Mayo Clinic review 2 emphasize that LMWH should overlap warfarin initiation for a minimum of 5 days AND until INR exceeds 2.0 for at least 24 hours.
Duration Specifics
Typical timeline: 5-7 days of enoxaparin
The enoxaparin duration depends on:
- INR response: Most patients achieve therapeutic INR (≥2.0) within 5-7 days 2
- Warfarin dosing: Initial doses of 5-10 mg daily for stable outpatients 2
- Patient factors: Elderly patients, poor nutritional status, or liver disease may require longer overlap 2
Critical Pitfall to Avoid
Do NOT stop Eliquis and start warfarin alone. Apixaban has a half-life of 9-14 hours 4, meaning anticoagulant effect diminishes within 24-48 hours. Warfarin takes 5-7 days to achieve therapeutic effect. This creates a dangerous gap where the patient is inadequately anticoagulated, particularly problematic in high-risk conditions like atrial fibrillation or recent VTE.
Special Considerations
For patients with renal impairment (CrCl <30 mL/min):
- Use caution with enoxaparin due to accumulation 2
- Consider dose adjustment or anti-Xa monitoring
- Enoxaparin is contraindicated if CrCl <30 mL/min per some sources 2
For cancer patients:
- The same overlap protocol applies 5
- Consider whether warfarin is the optimal long-term choice, as LMWH monotherapy is often preferred 6
Why Not Just Stop Eliquis and Start Warfarin?
The Eliquis label explicitly states that "ELIQUIS affects INR, so that initial INR measurements during the transition to warfarin may not be useful" 1. The parenteral anticoagulant provides immediate anticoagulation while warfarin's effect develops, preventing the prothrombotic gap that occurs during warfarin initiation.